
    
      This study was divided into two stages. The first stage study was an early safety assessment
      study among 80 subjects. The first stage study was conducted gradually in 20 subjects aged
      18-50 years, 20 subjects aged 7-17 years, and 40 subjects aged 2-6 years. The second phase
      was a randomized, double-blind, controlled, non-inferiority phase III clinical trial in 1200
      healthy infants aged 2-6 years, to evaluate the immunogenicity and safety of the experimantal
      vaccine after immunization.
    
  